Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **doxorubicin**, an anthracycline antibiotic that intercalates DNA strands, inhibiting macromolecular biosynthesis; **cyclophosphamide**, an alkylating agent that interferes with DNA replication; and **nivolumab**, a monoclonal antibody that blocks the PD-1 receptor, enhancing immune responses against cancer cells. The combination is explored for its potential to induce immunogenic cell death and enhance anti-tumor immune responses.
- Other names
- Nivolumab + CANivolumab + Cyclophosphamide + Doxorubicin induction therapy
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + nivolumab.